Are Wall Street Analysts Bullish on Henry Schein Stock?

Barchart
Abrir em Barchart
Are Wall Street Analysts Bullish on Henry Schein Stock?

Valued at a market cap of $9.5 billion, Henry Schein, Inc. (HSIC) is a global healthcare solutions company that distributes medical and dental supplies, equipment, pharmaceuticals, and specialty products to healthcare practitioners and institutions. Headquartered in Melville, New York, the company serves more than one million customers across over 30 countries, including dental practices, physician offices, laboratories, ambulatory surgery centers, and other healthcare facilities. 

This healthcare company has underperformed the broader market over the past 52 weeks. Shares of HSIC have gained 20.1% over this time frame, while the broader S&P 500 Index ($SPX) has soared 8%. Moreover, over the past six months, the stock has surged 16.3%, compared to SPX’s 2.4% drop.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

Narrowing the focus, HSIC has also trailed the State Street Health Care Select Sector SPDR ETF (XLV), which surged 16.5% over the past 52 weeks.

www.barchart.com 

Henry Schein reported solid third-quarter fiscal 2026 results on Nov. 3, with revenue increasing 4% year over year to $3.47 billion, supported by growth across its global distribution, specialty products, and technology businesses. Internal sales growth was 3.4%, while acquisitions contributed another 0.7% to revenue growth. Its adjusted EPS increased 19.1% to $1.37, and adjusted EBITDA climbed to $321 million from $295 million a year earlier, with margins expanding 40 basis points to 9.24%. 

The company also raised its FY2026 adjusted EPS guidance to $5.50–$5.56 from $5.29–$5.39, while maintaining its revenue growth outlook of 4.5%–5.5%. Investors were impressed and sent the shares up 7% in the next trading session. 

For the current fiscal year, ending in December, analysts expect HSIC’s EPS to grow 9.7% year over year to $5.45. The company’s earnings surprise history is solid. It topped the consensus estimates in each of the last four quarters.

Among the 17 analysts covering the stock, the consensus rating is a "Moderate Buy,” which is based on eight “Strong Buy,” eight "Hold," and one "Strong Sell” ratings.  

www.barchart.com 

The configuration is slightly bearish than three months ago, with nine analysts suggesting a “Strong Buy” suggestion.     

On Oct. 14, Leerink Partners lowered its price target on Henry Schein to $92 from $96 while maintaining a “Market Perform” rating. The firm cited muted expectations for the dental group's quarterly performance and concerns about sluggish broader market demand, although it sees potential for company-specific growth opportunities and improved execution.

The mean price target of $96.62 suggests a 13.9% premium to its current price levels, while its Street-high price target of $110 implies a 29.7% potential upside. 


On the date of publication, Kritika Sarmah did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Nasdaq Futures Plunge as AI Selloff Rolls On Disney Just Boosted Its Dividend by 33%. That Gives DIS Stock Investors a Real Reason to Stick Around. The Worst Might Be Over for Somnigroup as Credit Metrics Improve HSBC Just Turned Bullish on Cisco Stock Again. Here’s Why It Expects 40% Upside.